Vitrafy Enters Strategic Commercial Agreement with IMV
Filed with ASX · · 3 pages · English
Vitrafy Life Sciences Ltd. on 6ix
In the deck
Earlier from Vitrafy Life Sciences
- Q1 FY26 Quarterly Activities Report and Appendix 4C
- FY25 Full Year Results Presentation - Amended
- FY25 Appendix 4E and Annual Report
- FY25 Full Year Results Presentation
- Leadership Transition at Vitrafy
Later from Vitrafy Life Sciences
- Q2 FY26 Quarterly Activities Report and Appendix 4C
- FY26 Appendix 4D and Half Year Report
- FY26 Half Year Results Presentation
- USAISR Completes Phase 2 Platelet Study
- Q3 FY26 Quarterly Activities Report and Appendix 4C
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences